A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

2024-513915-28-00 Protocol 950P1V02 Human pharmacology (Phase I) - Other Ended

Start 14 Jun 2019 · End 13 Nov 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 950P1V02

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 136
Countries 1
Sites 1

Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor

Key facts

Sponsor
Toray Industries Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
14 Jun 2019 → 13 Nov 2025
Decision date (initial)
2024-08-09
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513915-28-00
EudraCT number
2018-001336-22
ClinicalTrials.gov
NCT03872947

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor

VersionLevelCodeTermSystem organ class
21.1 LLT 10053571 Melanoma 10029104
21.0 PT 10061451 Colorectal cancer 100000004864
27.0 PT 10008593 Cholangiocarcinoma 100000004864
21.1 PT 10067946 Renal cell carcinoma 100000004864
20.0 PT 10033128 Ovarian cancer 100000004864
21.0 LLT 10049516 Malignant tumor 10029104
20.0 PT 10005003 Bladder cancer 100000004864
21.1 PT 10017758 Gastric cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Toray Industries Inc.

Sponsor organisation
Toray Industries Inc.
Address
Nihonbashi Mitsui Tower, 1-1 Nihonbashi-Muromachi 2-Chome 1-1 Nihonbashi-Muromachi 2-Chome
City
Chuo-Ku
Postcode
103-8666
Country
Japan

Scientific contact point

Organisation
Toray Industries Inc.
Contact name
Akira Kurihara

Public contact point

Organisation
Toray Industries Inc.
Contact name
Akira Kurihara

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 32 1
Rest of world
United States
104

Investigational sites

France

1 site · Ended
Centre Leon Berard
Dpt Medecine & INSERM 1052, 28 Rue Laennec, 69008, Lyon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2019-06-14 2025-11-13 2019-06-27 2024-11-22

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-04 France Acceptable
2024-08-07
2024-08-09
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-27 France Acceptable
2025-02-05
2025-02-07